Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ebima Clifford Okundaye
Chronic kidney disease has been linked to impaired activity of mitochondrial dysfunction along with oxidative intracellular mechanisms that result in the cascade of progressive damage within renal tubular cells. Several treatment options for mitochondrial dysfunction have been suggested to target the loss of nephrons via renal fibrosis and tubular senescence of the kidney cells by enhancing the mitochondrial activity of these cells via the NAD/NAD+ redox pathway as well as reduce the presence of fibrogenic intracellular inflammatory markers .
QRX-3 is a formulated novel drug designed to supply and optimize NAD+ mitochondrial availability and prevent this nephron loss .
In this study the investigators will evaluate the effect of intervention with this novel drug therapy on chronic kidney disease CKD population with slowly declining renal function.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
* Patient with Chronic kidney disease
* Estimated Glomerular function by MDRD of less than 60mls/min
* Patients with declining renal function ( as measured by eGFR by MDRD )
* Rate of decline of eGFR over the last one year of less than 20%
* Negative Serology markers for CKD etiology
* Provider perceived adherence to study follow up
You may not be if
Rapid rate of decline in kidney function of \> 20 % over last one year
Symptomatic renal failure
Presence of any suspected Acute renal failure superimposed
Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
